Results 11 to 20 of about 121,870 (265)

The Vigil Magnetometer for Operational Space Weather Services From the Sun‐Earth L5 Point [PDF]

Space Weather
Severe space weather has the potential to cause significant socio‐economic impact and it is widely accepted that mitigating this risk requires more comprehensive observations of the Sun and heliosphere, enabling more accurate forecasting of significant ...
J. P. Eastwood, P. Brown, W. Magnes, C. M. Carr, M. Agu, R. Baughen, G. Berghofer, J. Hodgkins, I. Jernej, C. Möstl, T. Oddy, A. Strickland, A. Vitkova   +12 more
doaj   +2 more sources

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

Clinical Medicine Insights: Oncology, 2022
Background: Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of furin and downstream TGF-β1 and TGF-β2.
John J Nemunaitis
exaly   +2 more sources

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

Vaccines, 2021
Aim: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Patients and Methods: Recurrent ovarian cancer patients (n = 21) enrolled in prior clinical trials.
Rodney P Rocconi, Robert A Barrington, Gladice Wallraven   +2 more
exaly   +3 more sources

Predicting conservation priority areas in Borneo for the critically endangered helmeted hornbill (Rhinoplax vigil)

Global Ecology and Conservation
The critically endangered helmeted hornbill (Rhinoplax vigil) is under threat around its Southeast Asian range due to hunting and habitat loss. Dependant on primary rainforest habitats, the species is thought to be highly sensitive to habitat disturbance.
C.E.R. Hatten, Y.Y. Hadiprakarsa, C.K.F. Lee, A. Jain, R. Kaur, A. Miller, S. Cheema, N.J. Au, S. Khalid, C. Dingle   +9 more
doaj   +2 more sources

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product [PDF]

Scientific Reports
Retrospective data support overall survival (OS) advantage to high clonal tumor mutation burden (cTMB), high clonal neoantigen load (cNEO) and low intratumor heterogeneity (ITH) in cancer patients who receive immunotherapy.
David Willoughby, Ernest Bognar, Laura Stanbery, Casey Nagel, Gladice Wallraven, Aman Pruthi, Nicholas Bild, Ericca Stamper, Donald Rao, Adam Walter, John Nemunaitis   +10 more
doaj   +2 more sources

Vigil [PDF]

Journal of General Internal Medicine, 2019
Jason Young
openalex   +3 more sources

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy [PDF]

Future Oncology
John J Nemunaitis
exaly   +2 more sources

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

Vaccines, 2021
Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis.
Vedin Barve, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal Barve, John Nemunaitis   +8 more
doaj   +1 more source

Evaluation of fall‐seeded cover crops for grassland nesting waterfowl in eastern South Dakota

Wildlife Society Bulletin, EarlyView., 2023
Cover crops are experiencing a revival among Midwestern farmers, and we assessed their attractiveness and safety for nesting ducks in South Dakota. Nest success was markedly lower in cover crops than in perennial cover during both years of our study, including 2019 which was a best‐case scenario for cover crops, with extremely wet conditions delaying ...
Charles W. Gallman, Todd W. Arnold, Eric S. Michel, Joshua D. Stafford   +3 more
wiley   +1 more source

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials

Frontiers in Oncology, 2022
In recent years, many clinical trials have shown the safety and efficacy of Gemogenovatucel-T (Vigil) in the treatment of advanced OC patients. The purpose of this study was to explore the safety and efficacy of Gemogenovatucel-T (Vigil) in the first ...
Yixin Zhang, Yixin Zhang, Li Zhang, Yuli Zhao, Yuli Zhao, Sen Wang, Sen Wang, Li Feng   +7 more
doaj   +1 more source